Product Information
BUPRENORPHINE-NALOXONE 4-1 MG SL FILM is a generic product labeled by Alvogen Inc., priced at $2.5762 per EA under NDC 47781035603. Its NADAC has been published 385 times since May 22, 2019.
FDA first approved this application on Jan 24, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
4; 1 mg/1; mg/1
Manufacturer
Alvogen Inc.NDC
47781035603
Classification
Generic
Dosage Form
FILM
Route
BUCCAL; SUBLINGUAL
Effective Date
9/23/2026
Active Ingredients
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE DIHYDRATEApproval Type
Generic (ANDA)
FDA Application
ANDA205954FDA Approved
1/24/2019
TE Code
AB
On Market Since
2/11/2019
Pharmacological Classes
Price Statistics
The NADAC for BUPRENORPHINE-NALOXONE 4-1 MG SL FILM has been published 385 times since May 22, 2019, and over the history we have for it it has declined 53.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.5762 per EA |
|---|---|
| All-time high | $5.5517 (Jan 15, 2020) |
| All-time low | $2.2093 (Nov 20, 2024) |
| 52-week high | $3.4851 |
| 52-week low | $2.2214 |
| Median price | $4.0558 |
| Average price | $4.0786 |
| Largest weekly change | +50.3% (Aug 21, 2024) |
| Weeks tracked | 385 |
| Tracking since | May 22, 2019 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alvogen Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Buprenorphine and Naloxone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUPRENORPHINE-NALOXONE 4-1 MG SL FILM?
The current National Average Drug Acquisition Cost (NADAC) for BUPRENORPHINE-NALOXONE 4-1 MG SL FILM, manufactured by Alvogen Inc., is $2.5762 per EA (NDC 47781035603), effective Sep 30, 2026.
How has the price of BUPRENORPHINE-NALOXONE 4-1 MG SL FILM changed over time?
Over the history we have for it, the NADAC for BUPRENORPHINE-NALOXONE 4-1 MG SL FILM has declined 53.4%. It has been tracked across 385 weekly CMS publications since May 22, 2019.
What are the highest and lowest recorded NADAC prices for BUPRENORPHINE-NALOXONE 4-1 MG SL FILM?
Since May 22, 2019, the NADAC for BUPRENORPHINE-NALOXONE 4-1 MG SL FILM has ranged from a low of $2.2093 (Nov 20, 2024) to a high of $5.5517 (Jan 15, 2020), with a median of $4.0558 per EA.
Are there cheaper alternatives to BUPRENORPHINE-NALOXONE 4-1 MG SL FILM?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as BUPRENORPHINE-NALOXONE 4-1 MG SL FILM in a comparable dosage form, but none are currently priced below it.
Who manufactures BUPRENORPHINE-NALOXONE 4-1 MG SL FILM?
BUPRENORPHINE-NALOXONE 4-1 MG SL FILM (NDC 47781035603) is labeled by Alvogen Inc., and CMS classifies it as a generic product.